跳至主要内容
临床试验/CTRI/2023/01/049202
CTRI/2023/01/049202进行中(未招募)3 期

on-inferiority, Randomized, Double- blind Clinical Trial for Comparing the Efficacy and Tolerability of Diclofenac diethylamine 1.16% w/w gel of JAMP Pharma vs Voltaren Emulgel® (Diclofenac diethylamine 1.16% w/w) of GlaxoSmithKline Consumer Healthcare Inc., Canada in Patients with acute localized muscle or joint injuries

JAMP Pharma Corporation0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
进行中(未招募)

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Diagnosed by physical examination with acute strains Grade I and II (as
  • classified by the American Medicine Association system) or sprains Grade I
  • and II (as classified by The West Point Ankle Grading System).
  • 2. Injury that has led to sprain/strain should have occurred within 24 h before
  • 3. Pain on movement of injured area [measured on a 100 mm visual analogue
  • scale (VAS), ranging from 0 (no pain) to 100 (unbearable pain)] = 35 mm
  • immediately prior to randomization.
  • 4. Able to understand the requirements of the clinical trial and to agree to return
  • for the required follow-up visits.
  • 5. Willing to provide voluntary written informed consent and data protection
  • declaration before any clinical trial related procedure is performed.

排除标准

  • 1. Ligament rupture or severe sprain not considered amenable to treatment with
  • topical NSAIDS alone.
  • 2. Open skin lesion in the injured area
  • 3. Clinical evidence of fracture
  • 4. Dermatological conditions, such as eczema or skin infections on the injured
  • 5. Use of medication (other than the study drugs) for the treatment of complaints caused by the affected area
  • 6. Other inflammatory or painful conditions (e.g. headache, toothache).
  • 7. Similar injury of the same area within the last 3 months
  • 8. Debilitating acute/chronic illness,
  • 9. Use of long-acting NSAIDs, cyclooxygenase (COX)-2 inhibitors or tramadol in
  • the previous 24 h; any other analgesics in the previous 6 h; use of any other
  • topical products applied to the target site (Treatment by rest, ice, compression,
  • or elevation prior to randomization is allowed).
  • 10. Use of Systemic corticosteroid or immunosuppressive drugs in the previous 8
  • 11. Pregnant or lactating or planning to become pregnant during the study period.
  • 12. Patients with or without chronic asthma in whom attacks of asthma, urticaria, or
  • acute rhinitis are precipitated by acetylsalicylic acid or other non-steroidal anti inflammatory agents
  • 13. History of OA, rheumatoid arthritis, chronic inflammatory disease (e.g., colitis)
  • or fibromyalgia.
  • 14. History of asthma, hypertension, myocardial infarction, thrombotic events,
  • stroke, congestive heart failure, impaired renal function or liver disease.
  • 15. History of gastrointestinal bleeding or peptic ulcer disease.
  • 16. Known allergy to aspirin or nonsteroidal anti-inflammatory drug (NSAID).
  • 17. Use of anticoagulants, ACE-inhibitors, cyclosporine, diuretics, lithium, or
  • methotrexate within the past month prior to entry into the study.
  • 18. Women of child-bearing age who are not surgically incapable of pregnancy and
  • are unwilling to use an acceptable method of birth control.
  • 19. Current participation or not yet completed period of at least 30 days since
  • ending other investigational device or drug trial(s);
  • 20. Unwillingness or inability to comply with the clinical trial procedures.
  • 21. Unwillingness to consent to storage, saving and transmission of pseudonymous
  • medical data for clinical trial reasons.
  • 22. Patients who are deemed to be legally incapacitated.
  • 23. Patients who are legally detained in an official institute.

研究者

相似试验